Candel Therapeutics Stock (NASDAQ:CADL)
Previous Close
$7.04
52W Range
$4.34 - $7.66
50D Avg
$5.29
200D Avg
$5.56
Market Cap
$356.86M
Avg Vol (3M)
$1.41M
Beta
-0.81
Div Yield
-
CADL Company Profile
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
CADL Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CTNM | Contineum Therapeutics, Inc. Class A Common Stock |
| MREO | Mereo BioPharma Group plc |
| EDIT | Editas Medicine, Inc. |
| PRQR | ProQR Therapeutics N.V. |
| CAPR | Capricor Therapeutics, Inc. |
| CABA | Cabaletta Bio, Inc. |
| KYTX | Kyverna Therapeutics, Inc. |
| GNLX | Genelux Corporation |
| ALDX | Aldeyra Therapeutics, Inc. |
| IMMP | Immutep Limited |